Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBITDA: 2009-2024

Historic EBITDA for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $93.1 million.

  • Ironwood Pharmaceuticals' EBITDA rose 194.45% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 24.15%. This contributed to the annual value of $93.1 million for FY2024, which is 109.85% up from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' EBITDA is $93.1 million, which was up 109.85% from -$945.4 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' EBITDA registered a high of $528.4 million during FY2021, and its lowest value of -$945.4 million during FY2023.
  • Its 3-year average for EBITDA is -$225.7 million, with a median of $93.1 million in 2024.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' EBITDA skyrocketed by 397.71% in 2021, and later tumbled by 640.05% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBITDA (Yearly) stood at $106.2 million in 2020, then spiked by 397.71% to $528.4 million in 2021, then plummeted by 66.87% to $175.1 million in 2022, then crashed by 640.05% to -$945.4 million in 2023, then surged by 109.85% to $93.1 million in 2024.